Objective: The aim of this study was to determine whether genetic variation at the cannabinoid receptor-1 (CNR1) locus could have an effect on adiposity, fat distribution and obesity-related metabolic disorders in Polish postmenopausal women. Design and Subjects: The A3813G (rs12720071), G1422A (rs1049353), A4895G (rs806368) and rs806381, rs10485170, rs6454674 and rs2023239 single-nucleotide polymorphisms of CNR1 were genotyped in 348 randomly selected postmenopausal women aged 50-60 years recruited from the Wroclaw city population. Measurements: CNR1 genotypes, anthropometric measures (body mass index (BMI), waist circumference (WC) and body fat distribution by dual energy X-ray absorptiometry) and metabolic parameters (glucose, lipid profile and Fasting Insulin Resistance Index for insulin resistance) were determined. Results: The 3813G allele was not significantly associated with higher body mass, BMI, WC, total fat or fat percentage, but was associated with higher android fat deposit (2971.78 ± 1655.08 vs 2472.64 ± 1300.53, P ¼ 0.007) and percentage of android fat (37.59 ± 8.45 vs 35.66 ± 7.63, P ¼ 0.062). No associations for the G1422A, A4895G, rs806381, rs10485170, rs6454674 and rs2023239 variants were observed. Conclusions: There is an association of the variants of CNR1 with obesity-related phenotypes in Polish postmenopausal women. As cannabinoid receptor type 1 is a drug target for obesity, pharmacogenetic receptor gene analysis of obesity treatment by endocannabinoid blockade may be of interest to identify the best responders.
Introduction
Menopausal obesity is a multifactorial disease. The energy imbalance that results in menopausal obesity occurs as a result of genetic background, hormonal changes and acquired changes in eating behavior and physical activity. 1 The endocannabinoid system comprises two cannabinoid receptor subtypes, CB1 and CB2, their endogenous ligands and the enzymes for ligand biosynthesis and degradation. 2 The CB1 receptor, encoded by the CNR1 gene, has the greatest expression in the central nervous system but also in several peripheral organs including liver, muscle and adipose tissue. [3] [4] [5] [6] Evidence suggests that CB1 and its endogenous ligands, the endocannabinoids, are involved in the regulation of energy balance, influencing feeding behavior and body weight. [4] [5] [6] The endocannabinoid receptor type 1 gene, CNR1, is located on 6q14-q15. Several human CNR1 polymorphisms have been recently described in the European-American, African-American and Japanese individuals in association with polysubstance abuse. 7 Thus, polymorphic variants of this gene may contribute to individual differences in susceptibility to obesity, changes in body fat distribution and related metabolic disorders. Russo et al. 8 showed that genetic variants of CNR1 were associated with obesity-related phenotypes in men, Peeters et al. 9 demonstrated that G1422A polymorphism in the CNR1 gene was associated with increased abdominal adiposity in obese men and Benzinou et al. 10 showed that CNR1 variations increased the risk for obesity and modulated body mass index (BMI) in a European population. These observations led us to hypothesize that genetic variation at the CNR1 locus could have an effect on adiposity, fat distribution and obesityrelated metabolic disorders in postmenopausal women.
Materials and methods
The study population consisted of 348 randomly selected postmenopausal women aged 50-60 years (mean age 55.42 ± 2.73 years) recruited from the Wroclaw city population with BMIs ranging from 17. ). Only women with a history of natural menopause not taking hormonal replacement therapy were included. None of the women smoked, were on special diets or used medications influencing lipid profile or glucose metabolism. Women with diabetes mellitus, previously recognized dyslipidemia or liver dysfunction were excluded from the study. The patients were informed of the aim and the methods of the study and gave their informed consent in writing. The study protocol was approved by the ethics committee of Wroclaw Medical University, Poland.
Anthropometric measurements
Anthropometric parameters such as body mass, body height and waist circumference (WC) were measured in all subjects. Body mass and height were measured to the nearest 0.1 kg, and height was measured to the nearest centimeter crown to heel without shoes. WC was measured at half distance between the costal angle and the iliac crests to the nearest 0.1 cm with a flexible inextensible plastic tape, with the subject standing straight with the abdomen relaxed, arms at the sides and feet together. The BMI was calculated from the equation: body mass (kg)/height-squared (m 2 ). The percentage of body fat and visceral fat deposit was assessed using the dual-energy X-ray absorptiometry method using a DPX ( þ ) Lunar device (Lunar Corp., Madison, WI, USA). The percentage of abdominal fat (android fat deposit) was calculated using a computerized method after measuring fat tissue volume in the area between the upper edge of the L2 disc and the lower edge of the L4 disc. This region is characterized by a high amount of visceral and subcutaneous fat, which have a crucial role in insulin resistance and the development of metabolic syndrome.
11,12
Biochemical measurements Blood for laboratory tests was collected between 0700 and 0900 hours after overnight fasting. Centrifuged serum for biochemical analysis and whole blood for genomic studies were stored until examination at À20 1C. Serum concentrations of glucose (G), total cholesterol, high-density lipoprotein cholesterol and triglycerides were measured by routine enzymatic methods (Olympus Au 560; BioMerieux, Marcy l'Etoile, France). Low-density lipoprotein cholesterol was calculated according to the Friedewald formula: cholesterol low-density lipoprotein (mg per 100 ml) ¼ total cholesterol (mg per 100 ml)-high-density lipoprotein cholesterol (mg per 100 ml)-(triglycerides (mg per 100 ml)/5). The serum insulin (I) and estradiol concentrations were measured by radioimmunological methods using commercial kits (Diagnostic Product's Corporation, Los Angeles, CA, USA). For the estimation of insulin resistance, Fasting Insulin Resistance Index was calculated as fasting glucose (mmol l 
Genetic studies
Whole genomic DNA was isolated from blood leukocytes using standard methods. CNR1 genotyping (A3813G, G1422A, A4895G and rs806381, rs10485170, rs6454674 and rs2023239) was performed by two multiplex PCRs and minisequencing.
In the first one, three fragments of CNR1 gene (347, 346 and 231 bp) were amplified using multiplex PCR mix containing: the specific three pairs of primers (see Table 1 To amplify the second group of the four fragments of CNR1 gene (205, 230, 280 and 304 bp) multiplex PCR mix was used. It was employed containing: the specific four pairs of primers (see Table 1 The amplified fragments were purified from oligonucleotides and free deoxyribonucleotide triphosphates by shrimp alkaline phosphatase and exonuclease I treatment (Fermentas, Vilnius, Lithuania).
The minisequencing method was based on the incorporation of single fluorescence-labeled dideoxynucleotides to the 3 0 end of the oligonucleotide that was correctly paired to the specific template DNA fragment using a SNaPshot kit (Applied Biosystems, Life Technologies, Carlsbad, CA, USA). The SNaPshot reaction was carried out using the oligonucleotides: 
Statistical analysis
Means and s.d. of some physical and biochemical variables were calculated for genotypes of analyzed polymorphisms. To compare means between genotypes the analysis of variance and post hoc test (least significant difference) were used. Frequencies of risk factors in genotypes were compared using the w 2 test.
Results
We investigated whether specific CNR1 polymorphisms were associated with anthropometric markers of obesity and fat distribution as well as parameters describing metabolic syndrome in Polish postmenopausal women.
The A3813G polymorphism. Genetic analysis for this polymorphism was performed in 346 women. The AA genotype was found in 70%, AG in 22% and GG in only 8% of the women. The frequency of the A allele was P ¼ 0.81 and of the G allele,
Because the GG genotype was present in only 8% of the individuals, the analysis was performed according to the A recessive model (AG þ GG vs AA). The whole group was divided into two subgroups according to genotype (AG þ GG vs AA). The anthropometric and metabolic characteristics of these subgroups are presented in Tables 2 and 3. Although analysis of variance, adjusted for covariates, indicated that the G allele was associated with higher body mass, BMI, WC, total fat and fat percentage, statistical significance was not observed. A significant positive association between the G allele and fat distribution was observed, with the G allele carriers having significantly higher android fat deposit (2971.78 ± 1655.08 vs 2472.64 ± 1300.53, P ¼ 0.007) and percentage of android fat (37.59 ± 8.45 vs 35.66 ± 7.63, P ¼ 0.062; Table 2 ). The latter difference did not achieve statistical significance.
No significant association between the genotype and metabolic parameters was observed ( Table 3) .
The G1422A polymorphism. Genetic analysis for this polymorphism was performed in 333 women. 
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The GG genotype was found in 62%, GA in 33% and AA in only 5% of the women. The frequency of the G allele was P ¼ 0.79 and of the A allele, Q ¼ 0.21 (P þ Q ¼ 1).
Because the AA genotype was present in only 5% of the individuals, the analysis was performed according to the G dominant model (AG þ AA vs GG) and indicated no association between the genotypes and any of the quantitative investigated variables (data not shown).
The A4895G polymorphism. Genetic analysis for this polymorphism was performed in all women studied. The AA genotype was found in 57%, AG in 33% and GG in 10% of the women. The frequency of the A allele was P ¼ 0.74 and of the G allele,
No association was observed between the genotypes of the A4895G polymorphism and any of the quantitative variables investigated, whatever the genetic model, that is, dominant or recessive (data not shown).
The rs806381 polymorphism. Genetic analysis for this polymorphism was performed in 310 women. The AA genotype was found in 38%, AG in 44% and GG in 18% of the women. The frequency of the A allele was P ¼ 0.60 and of the G allele,
The rs1048517070 polymorphism. Genetic analysis for this polymorphism was performed in 310 women. The AA genotype was found in 83%, AG in 16% and GG in 1% of the women. The frequency of the A allele was P ¼ 0.91 and of the G allele, Q ¼ 0.09 (P þ Q ¼ 1).
The rs6454674 polymorphism. Genetic analysis for this polymorphism was performed in 310 women. The TT genotype was found in 41%, TG in 44% and GG in 15% of the women. The frequency of the T allele was P ¼ 0.63 and of the G allele, Q ¼ 0.37 (P þ Q ¼ 1).
The rs2023239 polymorphism. Genetic analysis for this polymorphism was performed in 310 women. The TT genotype was found in 66%, TC in 31% and CC in 3% of the women. The frequency of the T allele was P ¼ 0.82 and of the C allele,
No association was observed between the genotypes of the rs806381, rs10485170, rs6454674 and rs2023239 polymorphisms and any of the quantitative variables investigated (data not shown).
We also found no association between basal serum estrogen levels and the CNR1 gene variants.
Discussion
Recent data suggest that the endocannabinoid system controls food intake via central, and lipogenesis via peripheral CB1 receptors. [4] [5] [6] A pharmacological blockade of endocannabinoid receptor 1 leads to weight loss and an improved metabolic risk profile in overweight and obese individuals. [13] [14] [15] Thus, it was hypothesized that genetic variation at the CNR1 locus could have an effect on adiposity. Many investigators have suggested than an association exists between various CNR1 gene polymorphisms and the parameters of obesity in various populations. [8] [9] [10] 16, 17 On the other hand, Lieb et al., 18 who studied 18 singlenucleotide polymorphisms in the CNR1 gene in 2415 Framingham Offspring Study participants, found no evidence for an association of CNR1 polymorphisms with BMI, waist circumference, or visceral or subcutaneous adipose tissue.
In our study, we examined seven CNR1 polymorphisms: A3813G, G1422A, A4895G and rs806381, rs10485170, rs6454674 and rs2023239. We observed that the G allele of the A3813G polymorphism was associated with higher body mass, BMI, WC, total fat and fat percentage, although the differences were not statistically significant. Furthermore, G allele carriers had significantly higher android fat deposit. Similar observations were made in Italian and English men by Russo et al., 8 and in an European population by Benzinou et al., 10 whereas Jaeger et al. 16 observed no significant association between the 3813A/G polymorphism and any of the obesity-related traits in a Brazilian population. In our study, no associations between the genotypes of the G1422A polymorphism and the investigated anthropometric variables were observed. Peeters et al. 9 found that the CNR1
A1422A genotype was significantly associated with higher WHR, WC and fat mass percentage, but only in obese men. In obese women, no meaningful associations between CNR1 genotype and anthropometric parameters were found. Associations between the genotypes of the A4895G polymorphism and the investigated anthropometric variables were observed neither in our study nor in the studies of other researchers. 8 In our study, no associations between the genotypes of the rs806381, rs10485170, rs6454674 and rs2023239 polymorphisms and the investigated anthropometric variables were observed. The study of Benzinou et al., 10 performed on 5750 subjects, shows that these CNR1 variations increase the risk for obesity and modulate BMI in European population. Intronic single-nucleotide polymorphisms, rs806381 and rs2023239, which resisted correction for multiple testing, were further associated with higher BMI in both Swiss obese subjects and Danish individuals. 10 Furthermore, the genotyping of all known variants in partial linkage disequilibrium (r 2 40.5) with these two single-nucleotide polymorphisms in the initial case-control study identified two better associated single-nucleotide polymorphisms (rs6454674 and rs10485170).
One explanation for the differences in results observed in the previously mentioned studies may relate to population differences. For example, in our study only white postmenopausal women were considered. Furthermore, our population was smaller, and therefore generalization of these conclusions to other populations should be done with caution. What is more, body fat accumulation and body fat distribution result from the interaction of multiple genetic and lifestyle factors. 1, 19, 20 Clinical trials have shown that prolonged treatment with rimonabant, a pharmacological blocker of the CB1, not only effectively reduced body weight and abdominal fat, but also improved the metabolic profile in obese patients. [13] [14] [15] [16] Thus, we hypothesized that genetic variations at the CNR1 locus might lead to an alteration of endocannabinoid signaling that in turn may lead to differences in body fat accumulation, finally resulting in phenotype expression of a metabolic disorder. However, no association between any of the polymorphic variants of CRN1 and metabolic parameters was observed in our study in contrast to the study of Aberle et al. 21 These researchers observed that carriers of at least one A allele of the G1359A polymorphism in the CB1 gene following 3 months of a low-fat calorie-restricted diet lost more weight and reduced low-density lipoprotein cholesterol more than wild-type patients. 21 They concluded that genetic polymorphisms associated with obesity may become relevant only under the condition of a low-calorie diet and that the presence of certain genotypes may be associated with a more beneficial response to obesity treatment. In summary, our study showed an association of variants of CNR1 with obesity-related phenotypes in Polish postmenopausal women. As CB1 is a drug target for obesity, pharmacogenetic receptor gene analysis may be of interest to identify the best responders to endocannabinoid blockade therapy for obesity.
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